Pictet Asset Management (Switzerland)’s Neurocrine Biosciences NBIX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$87.2M	Buy	924,416 +200,172	+28%	+$19.6M	0.1%	210
2023 Q1	$73.3M	Buy	724,244 +142,767	+25%	+$14.9M	0.09%	236
2022 Q4	$69.5M	Sell	581,477 -70,401	-11%	-$8.25M	0.1%	229
2022 Q3	$69.2M	Sell	651,878 -419,919	-39%	-$42.6M	0.1%	228
2022 Q2	$104M	Buy	1,071,797 +296,422	+38%	+$27.4M	0.15%	189
2022 Q1	$72.7M	Buy	775,375 +363,942	+88%	+$30.8M	0.08%	255
2021 Q4	$35M	Sell	411,433 -938,417	-70%	-$86.3M	0.03%	413
2021 Q3	$129M	Buy	+1,349,850	New	+$128M	0.14%	190

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s NBIX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Neurocrine Biosciences (NBIX) stake by 28% in Q2 2023, buying an estimated $19.6M and bringing the position to 924,416 shares worth $87.2M. The position accounts for 0.1% of the portfolio, ranked #210.

Pictet Asset Management (Switzerland) first reported a position in NBIX in Q3 2021 and has held it in 8 quarters since. The position peaked at $129M in Q3 2021. 457 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Pictet Asset Management (Switzerland) held 924,416 shares of Neurocrine Biosciences worth $87.2M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 200,172 Neurocrine Biosciences shares in Q2 2023, an estimated $19.6M.
Neurocrine Biosciences made up 0.1% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #210 holding.
Pictet Asset Management (Switzerland) first reported a position in Neurocrine Biosciences in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Neurocrine Biosciences position peaked at $129M in Q3 2021.
457 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.